BONESUPPORT HOLDING AB (BOEUF)
OTHER OTC:BOEUF
BOEUF Stock Chart & Stats
$20.61
$0.00(0.00%)
At close: 4:00 PM EST
$20.61
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$17.66 - $35.00
Previous CloseN/A
Volume21.00
Average Volume (3M)123.00
Market Cap
$1.62B
Enterprise Value$14.73B
Total Cash (Recent Filing)$377.99M
Total Debt (Recent Filing)$15.88M
Price to Earnings (P/E)87.1
Beta0.17
Next Earnings
Apr 22, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding65,859,190
10 Day Avg. Volume111
30 Day Avg. Volume123
Financial Highlights & Ratios
PEG Ratio14.81
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio56.60
Enterprise Value/Market Cap9.07
Enterprise Value/Revenue12.54
Enterprise Value/Gross Profit13.55
Enterprise Value/Ebitda62.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.51
Revenue Forecast (FY)$161.47M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth & Product AdoptionConsistent high single- to double-digit constant-currency revenue growth and rapid adoption of antibiotic‑eluting CERAMENT show durable clinical demand and scalable commercial traction. Broad U.S. account expansion and strong LTM growth imply a repeatable procedure-driven revenue base over the next 2–6 months and beyond.
Exceptional Margins & Cash GenerationExtremely high product gross margins and improving adjusted operating margins underpin durable profitability. Operating and free cash flow turned strongly positive with 2025 cash conversion near 1x, supporting reinvestment in commercialization and R&D while providing a buffer against cost or tariff pressures over the medium term.
Conservative Balance Sheet & Low LeverageVery low leverage and growing equity/assets provide meaningful financial flexibility to fund regulatory pathways, clinical evidence generation, and geographic expansion without refinancing risk. The conservative capital structure reduces downside risk from isolated market or regulatory setbacks and supports multi-period strategic investments.
Bears Say
Regulatory Timing Risk For CERAMENT VReclassification to a De Novo pathway extends approval timing and increases execution uncertainty. Management’s conservative guidance excluding CERAMENT V revenue limits near-term upside and means potential sales are contingent on a longer regulatory timeline and additional evidence, delaying material contribution to growth.
Rising Commercial & Distributor CostsStructural increases in selling expenses and distributor commissions as the company scales U.S. launches and training programs will pressure operating leverage. Until per-account usage and clinical adoption deepen, higher recurring commercial costs may compress margins and constrain free cash flow expansion.
Regional Headwinds And Early Segment AdoptionSignificant Germany market reforms and protocol changes are creating a durable drag on European revenue, while spine and revision arthroplasty adoption remains early and evidence‑dependent. These regional and segmental adoption lags can produce uneven growth and delay realization of scale economics across markets.
BONESUPPORT HOLDING AB News
BOEUF FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was $17.66 and its highest was $35.00 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is $1.62B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Apr 22, 2026 which is in 11 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Feb 24, 2026. The company reported $0.072 earnings per share for the quarter, missing the consensus estimate of $0.094 by -$0.023.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.11.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of $0.072 in its last earnings report, missing expectations of $0.094. Following the earnings report the stock price went up 2.872%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in BOEUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
BOEUF Company Deck
BOEUF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: strong underlying sales growth (especially CERAMENT G in the U.S.), high gross margins, solid adjusted profitability and cash generation, plus continued geographic and product expansion (spine launch, De Novo path for CERAMENT V). Offsetting risks include currency translation headwinds that depressed reported growth, headwinds in Germany, rising commercial costs and distributor fees, newly introduced U.S. tariffs, and regulatory timing/uncertainty around CERAMENT V. Early-stage adoption in many newly opened accounts is still developing and some segments (spine, revision arthroplasty) require more evidence. Overall, the positives materially outweigh the challenges, with the company signaling confidence in 2026 constant-currency growth guidance (at least ~35%).View all BOEUF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
8.96% Mutual Funds
― Other Institutional Investors
86.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---